1. Combining the lack of chromogranins with chronic L-DOPA treatment affects motor activity in mice
- Author
-
José David Machado, Leandro Castañeyra-Ruiz, Agustín Castañeyra, Ayoze González-Santana, and Ricardo Borges
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Histology ,Dopamine Agents ,Substantia nigra ,Striatum ,Motor Activity ,Open field ,Pathology and Forensic Medicine ,Levodopa ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Dopamine ,Internal medicine ,Chromogranins ,Animals ,Medicine ,Benserazide ,business.industry ,Parkinsonism ,Cell Biology ,medicine.disease ,Motor coordination ,030104 developmental biology ,Endocrinology ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
We have tested whether the lack of chromogranins (Cgs) A and B could provoke CNS disorders when combined with an excess of dopamine. We chronically treated (over 6 months) mice lacking both chromogranins A and B (Cgs-KO) with a low oral dosage of L-DOPA/benserazide (10/2.5 mg/kg). Motor performance in the rota-rod test, open field activity, and metabolic cages indicated a progressive impairment in motor coordination in these mice, and an increase in rearing behavior, which was accompanied by an increase in DA within the substantia nigra. We conclude that mild chronic L-DOPA treatment does not produce nigro-striatal toxicity that could be associated with parkinsonism, neither in control nor Cgs-KO mice. Rather, Cgs-KO mice exhibit behaviors compatible with an amphetamine-like effect, probably caused by the excess of catecholamines in the CNS.
- Published
- 2020
- Full Text
- View/download PDF